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actors Related to the Selection of Surgical Versus
ercutaneous Revascularization in Diabetic Patients
ith Multivessel Coronary Artery Disease in the
ARI 2D (Bypass Angioplasty Revascularization
nvestigation in Type 2 Diabetes) Trial
auren J. Kim, PHD,* Spencer B. King, III, MD,† Kenneth Kent, MD,‡
aria Mori Brooks, PHD,§ Kevin E. Kip, PHD, J. Dawn Abbott, MD,¶
lice K. Jacobs, MD,# Charanjit Rihal, MD,** Whady A. Hueb, MD,†† Edwin Alderman, MD,‡‡
van R. Pena Sing, MD,‡‡ Michael J. Attubato, MD,§§ Frederick Feit, MD,§§
or the BARI 2D (Bypass Angioplasty Revascularization Investigation Type 2 Diabetes) Study Group
ethesda, Maryland; Atlanta, Georgia; Washington, DC; Pittsburgh, Pennsylvania;
ampa, Florida; Providence, Rhode Island; Boston, Massachusetts; Rochester, Minnesota;
ão Paulo, Brazil; Stanford, California; and New York, New York
bjectives We evaluated demographic, clinical, and angiographic factors inﬂuencing the selection
f coronary artery bypass graft (CABG) surgery versus percutaneous coronary intervention (PCI) in
iabetic patients with multivessel coronary artery disease (CAD) in the BARI 2D (Bypass Angioplasty
evascularization Investigation in Type 2 Diabetes) trial.
ackground Factors guiding selection of mode of revascularization for patients with diabetes melli-
us and multivessel CAD are not clearly deﬁned.
ethods In the BARI 2D trial, the selected revascularization strategy, CABG or PCI, was based on
hysician discretion, declared independent of randomization to either immediate or deferred revas-
ularization if clinically warranted. We analyzed factors favoring selection of CABG versus PCI in
,593 diabetic patients with multivessel CAD enrolled between 2001 and 2005.
esults Selection of CABG over PCI was declared in 44% of patients and was driven by angiographic
actors including triple vessel disease (odds ratio [OR]: 4.43), left anterior descending stenosis 70% (OR:
.86), proximal left anterior descending stenosis 50% (OR: 1.78), total occlusion (OR: 2.35), and multiple
lass C lesions (OR: 2.06) (all p  0.005). Nonangiographic predictors of CABG included age 65 years
OR: 1.43, p  0.011) and non-U.S. region (OR: 2.89, p  0.017). Absence of prior PCI (OR: 0.45, p  0.001) and
he availability of drug-eluting stents conferred a lower probability of choosing CABG (OR: 0.60, p  0.003).
onclusions The majority of diabetic patients with multivessel disease were selected for PCI rather than
ABG. Preference for CABG over PCI was largely based on angiographic features related to the extent,
ocation, and nature of CAD, as well as geographic, demographic, and clinical factors. (Bypass Angioplasty Re-
ascularization Investigation in Type 2 Diabetes [BARI 2D]; NCT00006305) (J Am Coll Cardiol Intv 2009;2:
84–92) © 2009 by the American College of Cardiology Foundation
rom the *National Institute on Aging, Bethesda, Maryland; †Saint Joseph’s Heart and Vascular Institute, Atlanta, Georgia;
Washington Hospital Center, Washington, DC; §University of Pittsburgh, Pittsburgh, Pennsylvania; University of South
lorida, Tampa, Florida; ¶Brown University/Rhode Island Hospital, Providence, Rhode Island; #Boston University School of
edicine/Boston Medical Center, Boston, Massachusetts; **Mayo Clinic, Rochester, Minnesota; ††University of São Paulo Heart
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385atients with diabetes mellitus (DM) who comprise approx-
mately 25% of the 1.5 million undergoing coronary revas-
ularizations annually in the U.S. experience worse out-
omes after both coronary artery bypass graft surgery
CABG) and percutaneous coronary intervention (PCI)
han those without DM (1–4). Determination of the
ppropriate revascularization strategy for an individual patient
s a complex issue that is of great importance, considering the
rowing number of patients with DM and coronary artery
isease (CAD). In the original BARI (Bypass Angioplasty
evascularization Investigation) trial, patients with medically
reated DM and multivessel disease randomized to CABG
ersus PCI, limited to balloon angioplasty, had a significantly
ower long-term mortality, which prompted the National
eart, Lung, and Blood Institute to issue a Clinical Alert
ecommending CABG over angioplasty in this high-risk
ubset (5,6). However, findings from the BARI registry, in
hich selection of revascularization strategy was at the discre-
ion of the treating physician, showed nearly identical 7-year
urvival with PCI or CABG in patients with diabetes, even
hen the data were adjusted for covariates (7).
In the years since the BARI trial results were first
eported, advances in PCI technology and adjunctive ther-
pies have significantly improved clinical outcomes. In
articular, the use of stents, glycoprotein IIb/IIIa receptor
nhibitors, and the direct thrombin inhibitor bivalirudin
ave substantially lowered restenosis and acute ischemic
nd/or bleeding complication rates (1,8–13). Furthermore,
growing appreciation for the critical role of intensive
edical management and attention to cardiovascular risk
actors has led to the widespread use of statins, beta-
lockers, and angiotensin-converting enzyme inhibitors
14–16). These improvements in therapy have not changed
merican College of Cardiology/American Heart Associa-
ion practice guidelines, which recommend that, in general,
atients with less extensive CAD be treated with PCI, while
hose with more extensive and severe disease be referred for
ABG (17,18). In addition, regional differences in the
reatment of ischemic heart disease have been previously
escribed (19,20). Therefore, we evaluated demographic,
linical, geographic, and angiographic factors that influ-
nced the selection of CABG versus PCI in patients with
M and multivessel CAD with stable symptoms enrolled in
he BARI 2D (Bypass Angioplasty Revascularization Inves-
igation in Type 2 Diabetes) trial.
nstitute, São Paulo, Brazil; ‡‡Stanford University, Stanford, California; and the
§New York University School of Medicine, New York, New York. The BARI 2D
tudy is funded by the National Heart, Lung, and Blood Institute and the National
nstitute of Diabetes and Digestive and Kidney Diseases (U01 HL061744, U01
L061746, U01 HL061748, U01 HL063804). The BARI 2D study receives
ignificant supplemental funding from GlaxoSmithKline; Bristol-Myers Squibb
edical Imaging, Inc.; Astellas Pharma US, Inc.; Merck & Co., Inc.; Abbottaboratories, Inc.; and Pfizer, Inc.; and generous support from Abbott Laboratories
td.; MediSense Products; Bayer Diagnostics; Becton, Dickinson and Company; J. R. aethods
tudy design. The BARI 2D trial has a randomized 2  2
actorial design to compare treatment strategies in patients
ith DM and CAD with stable symptoms: 1) immediate
oronary revascularization plus intensive medical therapy
ersus intensive medical therapy alone with deferred revas-
ularization, as needed, for treatment of CAD; and 2) an
nsulin-providing strategy versus insulin-sensitizing strategy
or treatment of DM. After angiographic evaluation, and
efore randomization to immediate versus deferred revas-
ularization, the mode of revascularization with either
ABG or PCI was selected and declared by the clinical site
tudy physicians. Patient preference was not recorded. A
etailed description of the protocol has been published (21).
n brief, eligibility criteria required angiographically docu-
ented CAD involving at least 1 coronary artery (50%
tenosis) suitable for treatment with either medical therapy
lone or elective revascularization with CABG or PCI, and
ocumented myocardial isch-
mia or at least 1 70% stenosis
ith stable angina. Exclusion
riteria included left main steno-
is 50%, any prior CABG or
CI in the past 12 months. A
otal of 2,368 participants en-
olled from 49 clinical sites in
he U.S., Brazil, Canada, Mex-
co, the Czech Republic, and
ustria between January 1,
001, and March 31, 2005, have
een described (22).
In the present analysis, we
xcluded patients with single-
essel disease (n  611), those
ho had previously undergone CABG (n 152), and those
ith 80% complete baseline data or without clinical site
valuation of the baseline angiogram (n  35). Thus, the
tudy population included 1,593 patients with multivessel
AD from U.S. (n  910) and non-U.S. (n  683) sites.
Angiographic characteristics were assessed at the clinical
ites and by a core laboratory (Stanford University). For this
nalysis, site-determined angiographic variables are reported
ince they were utilized to determine the mode of revascu-
arization. However, myocardial jeopardy index (MJI),
arlson Laboratories, Inc.; Centocor, Inc.; Eli Lilly and Company; LipoScience, Inc.;
erck Sante; Novartis Pharmaceuticals Corporation; and Novo Nordisk, Inc. Dr.
eit is a major shareholder of Eli Lilly and Novartis. A complete list of the BARI 2D
tudy Group has been published previously in reference 22. Morton Kern, MD, acted
s Guest Editor for this paper.
anuscript received October 17, 2008; revised manuscript received January 9, 2009,
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft surgery
CAD  coronary artery
disease
CI  confidence interval
DES  drug-eluting stent(s)
DM  diabetes mellitus
MJI  myocardial jeopardy
index
OR  odds ratio
PCI  percutaneous
coronary interventionccepted January 28, 2009.
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386hich reflects the percentage of jeopardized myocardium,
as determined by the core lab (23). Because MJI does not
ccount for territories previously revascularized by either
ABG or PCI, patients with prior PCI (n  285) were
xcluded from the presentation of MJI data.
tatistical methods. Demographic, clinical, and angio-
raphic characteristics related to the choice of CABG versus
CI were compared, using the chi-square test for categor-
cal variables and the Cochran-Armitage trend test for
rdinal variables, for the overall cohort and stratified by
egion (U.S. and non-U.S.). We examined the choice of
evascularization procedure by MJI, and compared the U.S.
ersus the non-U.S. clinical centers.
Multivariable analysis of the “CABG selection” outcome
as performed using a nonlinear mixed model that included
random-effect intercept term for each clinical site (24).
hese models incorporate the multilevel nature of treatment
election, based both on physician judgment and patient-
evel characteristics, and account for the correlation between
bservations within a site. The odds ratio (OR) for a
atient-level factor (e.g., age) in a mixed model is inter-
reted as the estimated effect of the factor on the decision to
hoose CABG within an individual site, while the OR for
site-level factor such as geographic region is interpreted as
he estimated odds of choosing CABG among sites in 1
egion versus another region adjusting for population dif-
erences between sites. Variable selection was accomplished
sing standard logistic regression (25). Forward stepwise
ariable-selection methods were used to construct separate
ultivariable models for: 1) demographic and clinical char-
cteristics; 2) cardiovascular medications; 3) site angio-
raphic measurements; and 4) core lab angiographic mea-
urements. In addition to the variables listed in Tables 1 to
, candidate variables included angina status, history of
ypercholesterolemia, renal dysfunction, chronic obstructive
Table 1. Intended Revascularization Strategy by Geographic Region and Ti
No. of Clinical Sites
Total 49
By region
U.S. 40
Non-U.S. 9
Brazil (Sao Paulo) 1
Canada 5
Mexico (Mexico City) 1
Europe‡ 2
By date of randomization§
U.S./Canada on or before April 25, 2003 39
U.S./Canada after April 25, 2003 39
Row percentages are presented. *Comparison of U.S. vs. non-U.S. regions using chi-square test; †co
randomized patients before April 25, 2003. Drug-eluting stents became available on April 25, 2003BARI 2D Bypass Angioplasty Revascularization Investigation in Type 2Diabetes trial; CABG coronary arteulmonary disease, pulmonary edema, history of malig-
ancy, smoking status, body mass index, glycosylated he-
oglobin, presence of Q waves, ST-segment depression,
T-segment elevation, inverted T waves, or any major
lectrocardiographic abnormality, left ventricular ejection
raction 50%, serum creatinine, as well as right coronary
rtery and circumflex variables similar to the left anterior
escending coronary artery (LAD) variables presented in
able 3. Factors identified from these models were com-
ined, and geographic region (non-U.S. vs. U.S.) and time
f randomization (before vs. after April 25, 2003, when
ES became available at U.S. and non-U.S. sites) were
dded to the model. Covariates with a value of p  0.05
ere subsequently removed using backward selection. Sta-
istical interactions between geographic region and main
ffects variables were tested, and interaction terms with a
alue of p  0.01 were retained. Each of the interaction
erms involving geographic region and the other explanatory
ariables had a p value 0.01 when added to the multiva-
iable model; as a result, the final model does not include
ny interaction terms. Finally, a mixed model with random
ntercepts was created using the selected variables. The
odel intraclass correlation, representing the proportion of
he total unexplained variability in treatment selection
ccounted for by clinical site, is reported (25). Estimates for
Rs, 95% confidence intervals (CIs), and p values are
resented, and a value of p  0.05 was considered statisti-
ally significant. All statistical analyses were performed
sing SAS version 9.1 (SAS Inc., Cary, North Carolina).
esults
ariation in treatment selection by region and time. Among
he 1,593 diabetic patients with multivessel coronary dis-
ase, the decision to select CABG and PCI was declared in
ong Patients With Diabetes and Multivessel CAD in the BARI 2D Trial
Intended Procedure
No. of Patients CABG PCI p Value
1,593 44% 56%
910 31% 69% 0.001*
683 61% 39%
293 73% 27% 0.001†
271 47% 53%
62 76% 24%
57 56% 44%
656 39% 61% 0.0025
473 30% 70%
n across the 5 regions using chi-square test; ‡Czech Republic and Austria; §includes only sites that
.S.me Am
mpariso
in the Ury bypass graft surgery; CAD coronary artery disease; PCI percutaneous coronary intervention.
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3874% (n  703) and 56% (n  890), respectively. Of 890
atients in whom PCI was declared, 434 (49%) were
eemed suitable for CABG; of 703 patients intended for
ABG, 79 (11%) were deemed suitable for PCI. The main
easons that investigators preferred CABG among CABG-
ntended patients were the likelihood of success and safety,
ited in 97% and 46% of patients, respectively, while the
ain reasons for preferring PCI among PCI-intended
atients were the likelihood of success and physician pref-
rence cited in 66% and 26% of patients. Selection of
Table 2. Demographic and Clinical Characteristics Associated With the Se
All Patients (N  1,593)
n
Intended Procedure
VaCABG PCI
Demographic proﬁle
Sex Men 1,149 46% 54% 0
Women 444 38% 62%
Age 65 yrs No 949 42% 58% 0
Yes 644 47% 53%
Race White (NH) 1,055 47% 53% 0
Black (NH) 251 31% 69%
Hispanic 198 48% 52%
Other 89 36% 64%
HS education No 620 55% 45% 0
Yes 968 37% 63%
Health insurance Public 1,156 49% 51% 0
Private 368 32% 68%
None/self-pay 67 27% 73%
Clinical proﬁle
History of MI No 1,066 41% 59% 0
Yes 501 50% 50%
Prior PCI No 1,308 47% 53% 0
Yes 285 29% 71%
CHF No 1,500 45% 55% 0
Yes 86 36% 64%
Angina class No angina 309 42% 58% 0
Atypical 329 42% 58%
Stable 1/2 684 46% 54%
Stable 3/4 139 50% 50%
Unstable 132 36% 64%
Hypertension No 271 41% 59% 0
Yes 1,301 45% 55%
Stroke/TIA No 1,426 45% 55% 0
Yes 160 34% 66%
Diabetes duration (yrs)* 5 499 43% 57% 0
5–10 395 45% 55%
10 695 45% 55%
Insulin use No 1,171 47% 53% 0
Yes 422 37% 63%
Row percentages are presented. *Cochran-Armitage trend test p 0.05.
CHF congestive heart failure; HS high school; MImyocardial infarction; NH non-HispanABG rather than PCI was significantly lower in the U.S. tompared with non-U.S. sites (31% vs. 61%, p  0.001)
Table 1). Outside of the U.S., selection of CABG ranged
rom 47% in Canada, 56% in Europe, 73% in Brazil, to 76%
n Mexico (p  0.001 for trend). Substantial variability in
he selection of revascularization strategy existed among
articipating sites within the U.S. as well as outside of the
.S. (Fig. 1). In both U.S. and non-U.S. regions, the
ecision to select CABG increased as disease burden in-
reased, but within each MJI quartile, patients in the U.S.
ere significantly less likely to be selected for CABG than
n of CABG and PCI
U.S. (n  910) Non-U.S. (n  683)
n
Intended Procedure
p
Value n
Intended Procedure
p
ValueCABG PCI CABG PCI
640 34% 66% 0.002 509 62% 38% 0.70
270 24% 76% 174 60% 40%
514 27% 73% 0.003 435 60% 40% 0.29
396 36% 64% 248 64% 36%
533 33% 67% 0.04 522 61% 39% 0.003
208 24% 76% 43 67% 33%
134 36% 64% 64 75% 25%
35 26% 74% 54 43% 57%
224 31% 69% 0.90 396 68% 32% 0.001
682 31% 69% 286 52% 48%
519 33% 67% 0.26 637 61% 39% —
330 28% 72% 38 68% 32%
60 28% 72% 7 14% 86%
641 30% 70% 0.35 425 59% 41% 0.02
255 33% 67% 246 67% 33%
714 34% 66% 0.001 594 63% 37% 0.006
196 20% 80% 89 48% 52%
834 31% 69% 0.66 666 62% 38% 0.37
72 33% 67% 14 50% 50%
177 29% 71% 0.50 132 59% 41% 0.16
220 35% 65% 109 57% 43%
336 32% 68% 348 61% 39%
69 29% 71% 70 70% 30%
108 26% 74% 24 79% 21%
139 31% 69% 0.97 132 52% 48% 0.007
766 31% 69% 535 64% 36%
794 32% 68% 0.02 632 61% 39% 0.65
112 21% 79% 48 65% 35%
278 27% 73% 0.07 221 62% 38% 0.99
209 31% 69% 186 61% 39%
420 34% 66% 275 61% 39%
617 33% 67% 0.06 554 62% 38% 0.64
293 27% 73% 129 60% 40%
transient ischemic attack; other abbreviations as in Table 1.lectio
p
lue
.002
.05
.001
.001
.001
.001
.001
.12
.09
.25
.008
.5
.001hose in other countries (p  0.001) (Fig. 2). The date of
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388andomization was also a factor that influenced the revas-
ularization treatment decision. Among the 39 sites that
nrolled patients before April 25, 2003, the availability of
rug-eluting stents (DES) was associated with an increased
Table 3. Angiographic Characteristics Associated With the Selection of CA
All Patients (N  1,593
n
Intended Procedure
CABG PCI
Clinical site measurements
Vessel disease Double 746 25% 75%
Triple 847 61% 39%
Number of vessels 70%† 0 44 11% 89%
1 366 22% 78%
2 713 39% 61%
3 470 72% 28%
Proximal LAD 50% No 202 17% 83%
Yes 1,391 48% 52%
Any LAD 70% No 510 24% 76%
Yes 1,083 54% 46%
Maximum stenosis in any vessel (%)† 50–69 44 11% 89%
70–89 477 26% 74%
90–99 495 43% 57%
100 577 62% 38%
Any total occlusions No 1,016 34% 66%
Yes 577 62% 38%
Ejection fraction 40%‡ No 1,425 45% 55%
Yes 82 49% 51%
Core lab measurements
MJI (%)†§ 25 158 18% 82%
26–50 445 33% 67%
51–75 467 58% 42%
76–100 238 72% 28%
Proximal LAD 50% No 1,378 41% 59%
Yes 214 62% 38%
Total number of lesions† 3 313 25% 75%
4 331 39% 61%
5 300 46% 54%
6 239 50% 50%
7 409 59% 41%
Number of lesions 50%† 1 273 17% 83%
2 401 33% 67%
3 377 49% 51%
4 541 62% 38%
Number of class C lesions† 0 698 28% 72%
1 567 50% 50%
2 221 63% 37%
3 106 76% 24%
Any nondiscrete lesions No 612 38% 62%
Yes 980 48% 52%
Rowpercentages are presented. *Chi-square p values compare percentage of CABG-intendedpatien
for 86 patients; §excludes patients with prior PCI (n 285).
LAD left anterior descending coronary artery; MJImyocardial jeopardy index; other abbreviaelection of PCI (p  0.0025) (Table 1). tatient characteristics associated with the selection of CABG.
emographic and clinical factors associated with revascu-
arization selection for the entire group and stratified by
egion are presented in Table 2. Overall, the recommenda-
nd PCI
U.S. (n  910) Non-U.S. (n  683)
* n
Intended Procedure
p
Value* n
Intended Procedure
p
Value*CABG PCI CABG PCI
1 453 16% 84% 0.001 293 40% 60% 0.001
457 46% 54% 390 77% 23%
1 32 0% 100% 0.001 12 42% 58% 0.001
242 14% 86% 124 40% 60%
408 28% 72% 305 53% 47%
228 59% 41% 242 85% 15%
1 130 11% 89% 0.001 72 29% 71% 0.001
780 34% 66% 611 65% 35%
1 334 16% 84% 0.001 176 39% 61% 0.001
576 40% 60% 507 69% 31%
1 32 0% 100% 0.001 12 42% 58% 0.001
342 18% 82% 135 46% 54%
258 32% 68% 237 56% 44%
278 49% 51% 299 74% 26%
1 632 23% 77% 0.001 384 52% 48% 0.001
278 49% 51% 299 74% 26%
794 30% 70% 0.01 631 63% 37% 0.54
64 47% 53% 18 56% 44%
1 109 11% 89% 0.001 49 35% 65% 0.001
264 22% 78% 181 51% 49%
241 46% 54% 226 71% 29%
100 64% 36% 138 78% 22%
1 805 28% 72% 0.001 573 60% 40% 0.03
104 52% 48% 110 71% 29%
1 183 12% 88% 0.001 130 43% 57% 0.001
186 24% 76% 145 58% 42%
173 32% 68% 127 65% 35%
132 39% 61% 107 64% 36%
235 47% 53% 174 75% 25%
1 191 8% 92% 0.001 82 38% 62% 0.001
224 25% 75% 177 44% 66%
213 34% 66% 164 68% 32%
281 49% 51% 260 77% 23%
1 451 19% 81% 0.001 247 45% 55% 0.001
305 39% 61% 262 64% 36%
109 50% 50% 112 77% 23%
44 59% 41% 62 89% 11%
1 358 25% 75% 0.001 254 58% 42% 0.72
551 38% 62% 429 65% 35%
roups definedby variables listed;†Cochran-Armitage trend test p 0.05;‡ejection fractionmissing
s in Table 1.BG a
)
p
Value
0.00
0.00
0.00
0.00
0.00
0.00
0.47
0.00
0.00
0.00
0.00
0.00
0.00
ts for gion for CABG was more common in patients who were
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389hite or Hispanic and had not undergone a prior PCI. In
he U.S., patients who were male, age 65 years and older,
nd without a history of cerebrovascular events were more
ikely to be selected for CABG. Outside the U.S., less
ormal education, prior MI, and history of hypertension
ere associated with the selection of CABG.
Angiographic characteristics associated with the selec-
ion of revascularization strategy were consistent across
.S. and non-U.S. regions (Table 3). Patients with more
evere and extensive CAD, as indicated by triple- versus
ouble-vessel disease and extent of jeopardized myocar-
ium, were more likely to be selected for CABG (both
 0.001). Other angiographic features related to the
election of CABG over PCI included number of vessels
ith 70% stenosis; LAD stenosis 70%; number of
esions 50% stenosis; and total number of lesions,
rrespective of severity (all p  0.001). In addition, the
hoice of CABG was more common in patients with
omplex lesions, particularly total occlusions, class C
esions, and nondiscrete lesions (all p  0.001). An
jection fraction 40% was related to the selection of
ABG among patients in the U.S. (p  0.01).
ndependent predictors of the selection of CABG. The mul-
ivariable mixed model analysis indicated that after adjusting
or patient characteristics, the odds of selecting CABG was
igher among participants enrolled outside of the U.S. com-
ared with those enrolled in the U.S. (OR: 2.89, 95% CI: 1.22
o 6.83, p  0.017) (Fig. 3). Selection of CABG versus PCI
Figure 1. Multivessel CAD Patients Selected for CABG Within Clinical Site
Percentage of coronary artery bypass graft surgery (CABG)-intended patients p
median; Q1  ﬁrst quartile; Q3  third quartile.ithin clinical sites was driven largely by angiographic charac- ueristics related to severity of CAD including presence of
riple-vessel disease (OR: 4.43, 95% CI: 3.35 to 5.85,
 0.001), proximal LAD stenosis 50% (OR: 1.78, 95%
I: 1.20 to 2.64, p  0.005), any LAD stenosis 70% (OR:
.86, 95% CI: 2.11 to 3.88, p  0.001), total occlusion (OR:
.35, 95% CI: 1.76 to 3.13, p 0.001), and 2 or more class C
esions (OR: 2.06, 95% CI: 1.44 to 2.95, p 0.001). Age65
ears was also significantly associated with a preference for
ABG (OR: 1.43, 95% CI: 1.09 to 1.88, p  0.011).
onversely, CABG was less likely to be selected in patients
ho had previously undergone PCI (OR: 0.45, 95% CI: 0.31
o 0.64, p 0.001) and those randomized after April 25, 2003
OR: 0.60, 95% CI: 0.43 to 0.83, p  0.003). The “intrasite”
orrelation estimated from the mixed model was intraclass
orrelation  0.25 (p  0.001) indicating that the decision to
elect CABG versus PCI is strongly correlated with clinical
ite, although substantial within-site variability exists.
iscussion
n this analysis of the predictors of the selection of revas-
ularization strategy in patients from the BARI 2D trial
ith DM, multivessel CAD, and stable symptoms, we
ound that the choice of CABG rather than PCI was: 1)
ased largely on angiographic features related to a greater
xtent, severity, and complexity of CAD; 2) more likely in
atients 65 years of age and less likely in those who had
gion
for U.S. sites versus non-U.S. sites. CAD  coronary artery disease; Med by Re
er sitendergone a prior PCI; 3) more likely in non-U.S. than
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390.S. centers, with significant site-specific preferences within
he U.S.; and 4) less likely after the introduction of DES.
The multivariable analysis indicated that the angiographic
ndings that resulted in the selection of CABG, including
hronic total occlusions, triple-vessel disease, significant left
nterior descending coronary artery disease, presence of type C
esions, and extent of myocardial jeopardy, reflects existing
echnical limitations and evidence-based long-term outcomes
f PCI under specific anatomic circumstances (1,4–7,26).
mong demographic and clinical factors, only older age
directly) and prior PCI (inversely) were associated with the
election of revascularization strategy. Older age was associated
ith a greater probability of selecting CABG. This finding
ay be due partially to the trial design. Since study inclusion
riteria require a minimum 5-year expected survival and stable
resenting clinical status, elderly patients in the BARI 2D trial
ere, in general, likely to be in better health than elderly
atients seen in routine practice.
Substantial regional and temporal variations in the selec-
ion of mode of revascularization were detected. Practice
atterns in the U.S. were notable for lesser likelihood of
ABG as 54% of diabetic patients with triple-vessel disease
ere selected for PCI. The preference for surgical revascu-
arization outside of the U.S. was demonstrated at every
evel of myocardial disease burden, and this regional dis-
repancy remained significant after adjusting for differences
n clinical profiles and severity of CAD. The temporal shift
owards a preference for PCI in the BARI 2D trial after the
vailability of DES is consistent with the very rapid imple-
Figure 2. Likelihood of Intended CABG by MJI in U.S. and non-U.S. Sites
Percentage of coronary artery bypass grafting (CABG)-intended patients by myoca
out prior percutaneous coronary intervention (n  1,308). Note that for each quarentation of this technology that occurred for both ap- droved and off-label indications. There are several possible
xplanations for the regional variation in selection of CABG
ersus PCI. First, key high-level factors associated with the
ublic health care systems in Brazil, Canada, Mexico, and
urope may result in a preference for surgical revasculariza-
ion in these regions. Conversely, the greater use of PCI in
he U.S. may reflect an underlying philosophy that physi-
ians and patients favor the less invasive strategy whenever
echnically and clinically feasible.
mpact of the original BARI study results. Because the orig-
nal BARI trial pre-dated the use of stents or any device
ther than a balloon, its finding regarding the superiority of
ABG over conventional balloon angioplasty in diabetic
atients with multivessel CAD may have limited applica-
ility in contemporary practice. McGuire et al. (27) reported
hat 2 years after the Clinical Alert was issued, BARI study
esults did not impact practice patterns in the U.S., which
aried markedly throughout the country. This is not sur-
rising given the findings of nearly identical long-term
urvival in diabetic patients receiving PTCA versus CABG
y physician selection in the original BARI registry (7).
emarkably, there has been little change in the angio-
raphic predictors that drive a selection of CABG rather
han PCI in patients with multivessel CAD, from the era
hen only balloon angioplasty was available. Data from the
ARI registry, gathered between 1988 and 1991, indicated
hat just as in the BARI 2D trial, the selection of CABG
ather than PCI was driven by triple- versus double-vessel
opardy index (MJI) quartiles in U.S. and non-U.S. regions, among patients with-
MJI, non-U.S. patients were more likely to be selected for CABG.rdial jeisease, the number of significant lesions, and the presence
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391f a proximal left anterior descending coronary artery lesion,
ype C lesion(s), or diffuse disease (7).
tudy limitations. Several issues may limit the application of
ur findings. First, practice patterns in sites participating in the
ARI 2D trial may not reflect general practice. Specifically,
tudy investigators and patients from Brazil, Mexico, Czech
epublic, and Austria were each from a single center, and it is
ot clear that selection criteria at these sites represent those of
heir respective countries or regions. However, since treatment
election was at the discretion of local physicians, practice
atterns in all participating sites likely reflect the community
tandards of their respective centers. Second, study enrollment
ccurred as the first generation of DES were introduced, which
ecreased the percentage of patients selected for CABG.
ewer generations of DES may have already resulted in more
atients being selected for PCI. Third, a factor that did not
redict selection of CABG rather than PCI in this model, such
s a left ventricular ejection fraction 40% may have resulted
rom the relatively low number of patients with that finding
nrolled in the BARI 2D trial. Despite these limitations, the
ata presented were prospectively gathered on more than 1,500
atients across a broad spectrum of clinical sites and analyzed
y an independent data center. Furthermore, this analysis of
Class C lesions>=2
Total occlusions
Proximal LAD >=50% stenosis
LAD >=70% stenosis
Triple vessel disease
Prior PCI
Age >=65 years
Male sex
Rand. after DES available
Non US vs. US
0.45
0.6
Figure 3. Adjusted Odds Ratio of CABG Selection
Plot of independent predictors of the selection of coronary artery bypass graft
stable multivessel coronary disease. The red squares depict adjusted odds rat
stent(s); LAD  left anterior descending coronary artery; Rand.  Randomizedhe selection of revascularization strategy will be critical to the
Nnalysis of the primary study results and subsequent compari-
ons of those patients undergoing CABG versus PCI.
onclusions
mong patients with diabetes and multivessel CAD with
table symptoms in the BARI 2D trial, the decision to select
ABG over PCI was driven largely by angiographic fea-
ures associated with extent, location, and nature of CAD.
eographic region also played an important role, as a
reater preference for surgical revascularization was demon-
trated in countries outside of the U.S. irrespective of other
actors. Moreover, treatment selection varied substantially
cross geographic regions and across clinical sites within
egions, reflecting a lack of consensus regarding optimal
herapy in contemporary practice. Finally, the introduction
f the first generation DES decreased the likelihood of the
election of CABG.
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